Organogenesis Reports Strong FY2025, Warns of Significant Q1 2026 Revenue Decline Amid CMS Changes & ReNu Trial Setback
ORGO sits 46% above its 52-week low of $2.61.
Summary
Organogenesis reported strong FY2025 financial performance but warned of a significant Q1 2026 revenue decline due to adverse CMS reimbursement changes and a clinical trial failure for its ReNu product, alongside substantial potential dilution from preferred stock.
Key Events · Earnings and Guidance · ORGO
-
Strong FY2025 Financial Performance
Reported net product revenue of $563.0 million for fiscal year 2025, a 17% increase from 2024, and net income of $37.0 million, up from $0.86 million in 2024. Adjusted EBITDA also saw substantial growth to $98.1 million.
-
Significant Q1 2026 Revenue Decline Expected
The company anticipates a significant year-over-year decline in revenue for the first quarter of fiscal year 2026, primarily due to new Medicare reimbursement policies and the implementation of the WISeR Model for prior authorization.
-
Adverse CMS Reimbursement Changes
New CMS final rules effective January 1, 2026, establish a payment rate of approximately $127.14 per square centimeter for certain skin substitute products, which could materially and adversely impact product utilization, revenue, and profitability.
-
ReNu Phase 3 Clinical Trial Setback
The second Phase 3 Randomized Controlled Trial (RCT) for ReNu, targeting knee osteoarthritis, did not achieve statistical significance for its primary endpoint, despite a rolling Biologics License Application (BLA) submission initiated in H1 2026.
Analysis · ORGO · Life Sciences
Organogenesis Holdings Inc. reported strong financial results for fiscal year 2025, with net product revenue increasing by 17% to $563.0 million and net income rising significantly to $37.0 million. However, the company issued a concerning outlook for Q1 2026, anticipating a significant year-over-year revenue decline due to new CMS reimbursement policies and the implementation of the WISeR Model for prior authorization, which could materially impact product utilization and profitability. Further, a key pipeline product, ReNu, failed to achieve statistical significance for its primary endpoint in its second Phase 3 clinical trial, despite a rolling Biologics License Application (BLA) submission being initiated. The company also disclosed that its Series A Convertible Preferred Stock, issued in November 2024, could result in approximately 29% dilution if fully converted, significantly impacting existing shareholders. While the remediation of a material weakness in internal controls is a positive compliance development, the combination of a challenging near-term revenue outlook, a clinical trial setback, and substantial potential dilution presents significant headwinds for the company's investment thesis.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ORGO was trading at $3.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $469.6M. The 52-week trading range was $2.61 to $7.08. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.